[{"address1": "Prof. J.H. Bavincklaan 7", "city": "Amstelveen", "zip": "1183 AT", "country": "Netherlands", "phone": "31 20 793 2536", "website": "https://atai.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Amstelveen, The Netherlands.", "fullTimeEmployees": 54, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christian  Angermayer", "age": 46, "title": "Co-Founder & Chairman of the Supervisory Board", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 73104, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Srinivas G. Rao M.D., Ph.D.", "age": 55, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 834460, "exercisedValue": 0, "unexercisedValue": 39375}, {"maxAge": 1, "name": "Ms. Anne  Johnson", "age": 55, "title": "Chief Financial Officer", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 574815, "exercisedValue": 0, "unexercisedValue": 32812}, {"maxAge": 1, "name": "Dr. Gerd G. Kochendoerfer Ph.D.", "age": 56, "title": "Chief Operating Officer", "yearBorn": 1968, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Glenn  Short Ph.D.", "age": 54, "title": "Chief Scientific Officer", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Barrett J.D.", "age": 43, "title": "General Counsel & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevin  Craig M.D.", "age": 51, "title": "Chief Medical Officer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.45, "open": 5.45, "dayLow": 5.09, "dayHigh": 5.4821, "regularMarketPreviousClose": 5.45, "regularMarketOpen": 5.45, "regularMarketDayLow": 5.09, "regularMarketDayHigh": 5.4821, "payoutRatio": 0.0, "beta": 1.59, "forwardPE": -7.5, "volume": 4446932, "regularMarketVolume": 4446932, "averageVolume": 6000865, "averageVolume10days": 4712330, "averageDailyVolume10Day": 4712330, "bid": 4.97, "ask": 5.26, "bidSize": 47, "askSize": 47, "marketCap": 1192274816, "fiftyTwoWeekLow": 1.04, "fiftyTwoWeekHigh": 5.965, "allTimeHigh": 22.91, "allTimeLow": 1.025, "priceToSalesTrailing12Months": 516.3598, "fiftyDayAverage": 4.6888, "twoHundredDayAverage": 2.61155, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1009085504, "profitMargins": 0.0, "floatShares": 160106445, "sharesOutstanding": 233779400, "sharesShort": 16123373, "sharesShortPriorMonth": 17212180, "sharesShortPreviousMonthDate": 1756425600, "dateShortInterest": 1759190400, "sharesPercentSharesOut": 0.069, "heldPercentInsiders": 0.07709, "heldPercentInstitutions": 0.41076002, "shortRatio": 2.92, "shortPercentOfFloat": 0.090500005, "impliedSharesOutstanding": 245018794, "bookValue": 0.677, "priceToBook": 7.533235, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -119404000, "trailingEps": -0.69, "forwardEps": -0.68, "enterpriseToRevenue": 437.023, "enterpriseToEbitda": -10.639, "52WeekChange": 3.6363635, "SandP52WeekChange": 0.118204355, "quoteType": "EQUITY", "currentPrice": 5.1, "targetHighPrice": 16.0, "targetLowPrice": 7.0, "targetMeanPrice": 11.28571, "targetMedianPrice": 11.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 95943000, "totalCashPerShare": 0.448, "ebitda": -94849000, "totalDebt": 11716000, "quickRatio": 3.807, "currentRatio": 4.019, "totalRevenue": 2309000, "debtToEquity": 8.14, "revenuePerShare": 0.013, "returnOnAssets": -0.29507, "returnOnEquity": -0.76499003, "grossProfits": 2309000, "freeCashflow": -17686500, "operatingCashflow": -75571000, "revenueGrowth": 1.634, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -35.15021, "financialCurrency": "USD", "symbol": "ATAI", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1760140680, "regularMarketTime": 1760126401, "exchange": "NGM", "messageBoardId": "finmb_710359021", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -6.42202, "regularMarketPrice": 5.1, "shortName": "ATAI Life Sciences N.V.", "longName": "Atai Life Sciences N.V.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1624023000000, "postMarketChangePercent": -3.5294085, "postMarketPrice": 4.92, "postMarketChange": -0.17999983, "regularMarketChange": -0.35, "regularMarketDayRange": "5.09 - 5.4821", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 6000865, "fiftyTwoWeekLowChange": 4.06, "fiftyTwoWeekLowChangePercent": 3.9038463, "fiftyTwoWeekRange": "1.04 - 5.965", "fiftyTwoWeekHighChange": -0.86500025, "fiftyTwoWeekHighChangePercent": -0.14501262, "fiftyTwoWeekChangePercent": 363.63635, "earningsTimestamp": 1755057600, "earningsTimestampStart": 1763037000, "earningsTimestampEnd": 1763037000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.69, "epsForward": -0.68, "epsCurrentYear": -0.50333, "priceEpsCurrentYear": -10.132518, "fiftyDayAverageChange": 0.41120005, "fiftyDayAverageChangePercent": 0.087698355, "twoHundredDayAverageChange": 2.4884498, "twoHundredDayAverageChangePercent": 0.95286316, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-06-18", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "displayName": "Atai Life Sciences", "trailingPegRatio": null, "__fetch_time": "2025-10-11"}]